Dr. Anna Kulesza joins Nuclidium
Basel, Switzerland, January 15, 2023
Nuclidium AG is excited to welcome Dr. Anna Kulesza as our new CSO. Holding a PhD in Organic Chemistry from the University of Warsaw, Anna brings a wealth of experience from her postdoc at Procter & Gamble, significant roles at ETH Zürich, and program management at Lonza AG. She was pivotal in a major CAPEX project and advanced into targeted radiopharmaceutical therapy at Clovis Oncology in 2019. Now leading Nuclidium’s drug development and clinical programs since January 2024, Anna continues to make her mark in the pharmaceutical field.
For more information on Dr. Anna Kulesza: please see https://nuclidium.com/about-us/
